Dyadic International Inc at JPMorgan Healthcare Conference Transcript
Welcome to Dyadic's Investor Presentation. 2021 is setting up to be a breakthrough year for Dyadic, for our C1 technology platforms, adoption and use in animal health, and human health, infectious disease, and a variety of other applications. Additional risks can be found on our website at www.dyadic.com.
As we enter 2021, we have a solid financial position, strong insider ownership. But our greatest asset is a C1 gene expression platform, which has the capabilities and the potential to revolutionize the development and production of biologic vaccines, drugs, and other biologic products. In a relatively short time from our transition from industrial biotech to biopharmaceuticals, Dyadic and the C1 gene expression platform have started to embed itself in animal and human health, as well as infectious disease.
We've demonstrated through scientific data, which is growing and expanding, that we can produce things quickly in larger amounts at lower costs.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
